Cannara Biotech Inc
XTSX:LOVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cannara Biotech Inc
Depreciation & Amortization
Cannara Biotech Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cannara Biotech Inc
XTSX:LOVE
|
Depreciation & Amortization
CA$6.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Depreciation & Amortization
$1.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Depreciation & Amortization
CA$39.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
35%
|
|
|
Cronos Group Inc
TSX:CRON
|
Depreciation & Amortization
$14.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
66%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Depreciation & Amortization
CA$56.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
85%
|
|
Cannara Biotech Inc
Glance View
Cannara Biotech, Inc. is a pharmaceutical company, which operates cannabis biotech facility. The company is headquartered in Montreal, Quebec. The company went IPO on 2019-01-14. The firm operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. Its segments include Indoor cannabis operations and Real estate operations. The Indoor cannabis operations segment includes the cultivation, processing and sale of dried cannabis and cannabis derivatives exclusively for the Quebec and Canadian market. The Real estate operations segment is related to the Farnham building. The Company, through ShopCBD.com Inc., operates an online e-commerce platform in the United States hemp-based Cannabidiol (CBD) market. The firm sells dried cannabis products to provincial retail distributors and other licensed producers across Canada through Cannara Biotech (Quebec) Inc. The company owns approximately two cultivation facilities based in Quebec spanning over 1,650,000 square feet.
See Also
What is Cannara Biotech Inc's Depreciation & Amortization?
Depreciation & Amortization
6.7m
CAD
Based on the financial report for Nov 30, 2025, Cannara Biotech Inc's Depreciation & Amortization amounts to 6.7m CAD.
What is Cannara Biotech Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
19%
Over the last year, the Depreciation & Amortization growth was 7%. The average annual Depreciation & Amortization growth rates for Cannara Biotech Inc have been 16% over the past three years , 19% over the past five years .
